Effect of the semisynthetic form of glucagon-like peptide-2 analog in an experimental model of intestinal ischemia-reperfusion injury

Abstract

Ischemia-reperfusion injury (IRI) is inherent to intestinal transplant and is responsible for direct (early mucosal damage) and indirect injuries (lung disease). The loss of the mucosal barrier function and the structure of intestinal villi release proinflammatory cytokines, causing tissue damage in remote organs. Glucagon-like peptide-2 (GLP-2) is a hormone secreted by enteroendocrine L cells of the intestinal epithelium that has a trophic effect on in-testinal epithelium. Although therapeutic use of the semisynthetic form of GLP-2 (sGLP-2) in intestinal rehabilitation has been established, a few experimental studies have shown a potential use to reduce IRI. Our aim was to evaluate a possible protective effect of sGLP-2 in reducing local and remote organ IRI damage in a mouse model, as preliminary analysis to them be applied in further transplant models or in the clinical setting.